Cover Image
Market Research Report
Product code
757038

North America Opioids Drugs Market Forecast 2019-2028

Published: | Inkwood Research | 121 Pages | Delivery time: 2-3 business days

Price

Back to Top
North America Opioids Drugs Market Forecast 2019-2028
Published: May 11, 2020
Inkwood Research
Content info: 121 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

KEY FINDINGS

The North America opioids drugs market is anticipated to register a CAGR of 2.25% over the estimated period of 2019-2028. The increasing pharmaceutical expenditure, the growing prevalence, and a patient pool of opioid addiction and dependence, are some of the significant factors propelling market growth in the region.

MARKET FINDINGS

The North America opioids drugs market is further researched by dividing the region into the United States and Canada. Canada spends 11.5% of its GDP on healthcare, according to the OECD 2018 report. In Canada, the implementation of government policies, rising occurrence of opioids abuse, and strict regulatory measures for opioids drugs sale are hindering market growth in the region. The decreasing prescription volume of strong opioids is the primary factor affecting the growth of the market in the country. In 2017, about 4000 Canadians died from an opioid-related overdose. Moreover, from 2012-2016, the total number of daily doses for opioids reduced a little less than 5% all over Canada, but there is a steady increase in prescription opioids by 7%. Both the United States and Canada have taken stringent measures to control the epidemic nature of opioids usage and created guidelines for doctors, aimed at reducing opioid prescriptions. As per the PHN, opioid prescriptions lessened in 2017, and the overall quantity of distributed opioids decreased by 10.1% from 2016-2017. British Columbia, Canada's Pacific province was hit by coronavirus when already battling an opioid epidemic. In March, the Canadian government urged the provinces to lower restrictions on prescription medications.

COMPETITIVE INSIGHTS

Biodelivery Sciences International, Inc, Egalet Corp, Acura Pharmaceuticals, Inc, Johnson & Johnson, Pfizer Inc, etc. are some of the prominent companies functioning in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 22729

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. INCREASING ROAD ACCIDENTS AND SURGICAL PROCEDURES
    • 3.2.2. ESCALATING PALLIATIVE CARE FOR PATIENTS SUFFERING INTENSELY
    • 3.2.3. USAGE OF ABUSE DETERRENT FORMULATIONS TO RESTRICT THE OPIOID ABUSE
    • 3.2.4. GROWING OCCURRENCE OF CHRONIC PAIN
  • 3.3. KEY RESTRAINTS
    • 3.3.1. MISUSE OF OPIOIDS
    • 3.3.2. STRINGENT REGULATORY FRAMEWORK
    • 3.3.3. OPIOID CRISIS ACROSS THE GLOBE
    • 3.3.4. INCREASING NUMBER OF LAWSUITS CASES AGAINST OPIOIDS MANUFACTURERS
    • 3.3.5. RISING OCCURRENCE OF DEATHS RELATED TO OPIOID OVERDOSE

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. REGULATORY FRAMEWORK
  • 4.6. TECHNOLOGICAL ADVANCEMENT

5. MARKET BY PRODUCT

  • 5.1. BUPRENORPHINE
  • 5.2. FENTANYL
  • 5.3. HYDROCODONE
  • 5.4. MORPHINE
  • 5.5. OXYCODONE
  • 5.6. TRAMADOL
  • 5.7. OTHER PRODUCTS

6. MARKET BY APPLICATION

  • 6.1. PAIN RELIEF
    • 6.1.1. CANCER PAIN
    • 6.1.2. POSTOPERATIVE PAIN MANAGEMENT
    • 6.1.3. LOW BACK PAIN
    • 6.1.4. ORTHOPEDIC
    • 6.1.5. FIBROMYALGIA
    • 6.1.6. NEUROPATHIC
  • 6.2. ANESTHESIA
  • 6.3. COUGH SUPPRESSION
  • 6.4. DIARRHEA SUPPRESSION
  • 6.5. DEADDICTION

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA

8. COMPANY PROFILES

  • 8.1. ACURA PHARMACEUTICALS INC
  • 8.2. ALLERGAN PLC
  • 8.3. BIODELIVERY SCIENCES INTERNATIONAL INC
  • 8.4. CIPHER PHARMACEUTICALS INC
  • 8.5. COLLEGIUM PHARMACEUTICAL INC
  • 8.6. DAIICHI SANKYO INC
  • 8.7. EGALET CORP
  • 8.8. HIKMA PHARMACEUTICALS PLC
  • 8.9. INDIVIOR INC
  • 8.10. JANSSEN PHARMACEUTICALS INC
  • 8.11. JOHNSON & JOHNSON
  • 8.12. LANNETT CO. INC
  • 8.13. LUPIN LTD
  • 8.14. MYLAN NV
  • 8.15. PFIZER INC
  • 8.16. PURDUE PHARMA LP
  • 8.17. SANOFI-AVENTIS S.A
  • 8.18. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
  • 8.19. TEVA PHARMACEUTICAL INDUSTRIES LTD

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - OPIOIDS DRUGS
  • TABLE 2: FDA APPROVED OPIOIDS WITH ADF LABELLING
  • TABLE 3: NUMBER OF LAWSUITS CASES SETTLED BY OPIOIDS MANUFACTURING COMPANIES AND PHARMACIES, 2015-2027
  • TABLE 4: LIST OF ER/LA OPIOID BRANDED DRUGS, 2017
  • TABLE 5: LIST OF ER/LA OPIOID GENERIC DRUGS, 2017
  • TABLE 6: CDC GUIDELINES ON PRESCRIBING OPIOIDS
  • TABLE 7: PIPELINE ANALYSIS OF OPIOID DRUGS
  • TABLE 8: NORTH AMERICA OPIOIDS DRUGS MARKET, BY PRODUCT, HISTORICAL YEARS 2016-2019 (IN $ MILLION)
  • TABLE 9: NORTH AMERICA OPIOIDS DRUGS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA OPIOIDS DRUGS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: NORTH AMERICA OPIOIDS DRUGS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: NORTH AMERICA PAIN RELIEF MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION):
  • TABLE 13: NORTH AMERICA PAIN RELIEF MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: NORTH AMERICA OPIOIDS DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: NORTH AMERICA OPIOIDS DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: KEY INVESTMENT INSIGHTS
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: NORTH AMERICA OPIOIDS DRUGS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2019
  • FIGURE 6: NORTH AMERICA OPIOIDS DRUGS MARKET, BY BUPRENORPHINE, 2019-2028 (IN $ MILLION)
  • FIGURE 7: NORTH AMERICA OPIOIDS DRUGS MARKET, BY FENTANYL, 2019-2028 (IN $ MILLION)
  • FIGURE 8: NORTH AMERICA OPIOIDS DRUGS MARKET, BY HYDROCODONE, 2019-2028 (IN $ MILLION)
  • FIGURE 9: NORTH AMERICA OPIOIDS DRUGS MARKET, BY MORPHINE, 2019-2028 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA OPIOIDS DRUGS MARKET, BY OXYCODONE, 2019-2028 (IN $ MILLION)
  • FIGURE 11: NORTH AMERICA OPIOIDS DRUGS MARKET, BY TRAMADOL, 2019-2028 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA OPIOIDS DRUGS MARKET, BY OTHER PRODUCTS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA OPIOIDS DRUGS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2019
  • FIGURE 14: NORTH AMERICA OPIOIDS DRUGS MARKET, BY PAIN RELIEF, 2019-2028 (IN $ MILLION)
  • FIGURE 15: NORTH AMERICA PAIN RELIEF MARKET, BY CANCER PAIN, 2019-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA PAIN RELIEF MARKET, BY POSTOPERATIVE PAIN MANAGEMENT, 2019-2028 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA PAIN RELIEF MARKET, BY LOW BACK PAIN, 2019-2028 (IN $ MILLION)
  • FIGURE 18: NORTH AMERICA PAIN RELIEF MARKET, BY ORTHOPEDIC, 2019-2028 (IN $ MILLION)
  • FIGURE 19: NORTH AMERICA PAIN RELIEF MARKET, BY FIBROMYALGIA, 2019-2028 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA PAIN RELIEF MARKET, BY NEUROPATHIC, 2019-2028 (IN $ MILLION)
  • FIGURE 21: NORTH AMERICA OPIOIDS DRUGS MARKET, BY ANESTHESIA, 2019-2028 (IN $ MILLION)
  • FIGURE 22: NORTH AMERICA OPIOIDS DRUGS MARKET, BY COUGH SUPPRESSION, 2019-2028 (IN $ MILLION)
  • FIGURE 23: NORTH AMERICA OPIOIDS DRUGS MARKET, BY DIARRHEA SUPPRESSION, 2019-2028 (IN $ MILLION)
  • FIGURE 24: NORTH AMERICA OPIOIDS DRUGS MARKET, BY DEADDICTION, 2019-2028 (IN $ MILLION)
  • FIGURE 25: NORTH AMERICA OPIOIDS DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 26: THE UNITED STATES OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: CANADA OPIOIDS DRUGS MARKET, 2020-2028 (IN $ MILLION)